Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia
Key facts
- Who runs it
- SHAHLA KAREEM ALALAF
- Where
- Iraq1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 204 people enrolled
- Started
- 13 Dec 2024
- Ended
- 12 Jul 2025
- Type of study
- Observational, 2 groups
- Record updated
- 16 July 2025
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age group 18-45 years
- Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia
- Delivered vaginally or abdominally
- Being of any parity (para 1 and more)
- Pregnancy being singleton or multiple pregnancies
- Willingness to provide informed consent
Who cannot take part
- The lady on medications that can affect inflammatory markers or blood pressure
- Pregnant woman having chronic hypertension
- Having Diabetes mellitus
- Pregnant with fetal anomalies
- Refused to involve in the research
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia
The 2 groups in the trial
- Women with Preeclampsia
This group will comprise pregnant women having preeclampsia who are scheduled to undergo either vaginal or cesarean delivery. Their blood and their newborn blood will be collected and tested for a panel of inflammatory markers. This research aims to explore the potential association between maternal and neonatal inflammatory profiles and the development of preeclampsia, as well as its impact on pregnancy outcomes. By examining these markers, we hope to gain a better understanding of the underlying inflammatory mechanisms involved in preeclampsia.
- Normotensive pregnant women
This group will consist of normotensive pregnant women during delivery who are scheduled to have their blood and their newborn blood tested for a panel of inflammatory markers and responses to inflammatory markers. One of the aims of this research is to investigate the potential association between maternal and neonatal inflammatory profiles in normotensive pregnancy in comparison to women with preeclampsia and their newborn By examining these markers
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Maternal and Fetal Serum Soluble Fms-like Tyrosine Kinase-1, Seromucoid, and Protein-bound Hexose in Women With Pre-eclampsia: A Case-control Study
- Record updated
- 16 July 2025